Dynavax Technologies Corporation was founded in August 1996. The company discovers, develops and intends to commercialize products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, using proprietary approaches that alter immune system responses in specific ways. Its clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax s pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, which has completed a large-scale Phase 2/3 clinical trial, and is in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine that is in a pivotal Phase 3 clinical trial; a cancer therapy in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacologic activity in a Phase 2a clinical trial.

Steve M Sun, MD - MedAmerica Inc

John A Martin, MD - MedAmerica Inc

Ted W Love, MD - MedAmerica Inc

Gilley-Avramis, Joslin M MD